These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Leveling the hyperlipidemic effect of beta-adrenoblockers by means of antiatherogenic vegetarian diet].
    Author: Medkova IL, Ieromuzo AA, Ivanov AN, Mosiakina LI, Biriukova LS.
    Journal: Klin Med (Mosk); 2004; 82(6):58-60. PubMed ID: 15344694.
    Abstract:
    The purpose of the study was to examine the capacities of correction of impaired lipid metabolism in patients with CHD receiving selective beta-adrenoblockers (beta-AB) by using an antiatherogenic milk-and-vegetable diet. According to the type of antiatherogenic diet, 67 patients were divided into 2 groups: 1) 42 patients were on an antiatherogenic vegetarian diet (a vegetarian group--VG) and 2) 25 patients received routine mixed diet No. 10c (a control group--CG). At the same time all the patients received similar antianginal drug therapy including the selective beta-AB atenolol in a dose of 50 mg/day. The vegetarian diet without special hypolipidemic therapy had a marked normalizing effect on the serum lipid spectrum in patients with CHD. Thus, in VG, by the end of treatment, the level of total cholesterol significantly decreased by 16% while in the controls it increased by 13%. High-density lipoprotein cholesterol increased in VG and decreased in CG, therefore the atherogenicity coefficient considerably rose. These were true for triglycerides and very low-density lipoprotein cholesterol. These parameters significantly decreased in VG (by more than 30%) and increased in CG (by 16%). Among the clinical symptoms, a more pronounced decrease in blood pressure in the patients on vegetarian diet and a more significant increase in their exercise tolerance. Balanced antiatherogenic milk-and-vegetable diet in patients with coronary heart disease prevents the hyperlipidemic effect caused by the selective beta-AB atenolol and it is an agent for preventing its negative effect on lipid metabolism.
    [Abstract] [Full Text] [Related] [New Search]